Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

128 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer.
Najjar YG, Finke JH. Najjar YG, et al. Among authors: finke jh. Front Oncol. 2013 Mar 15;3:49. doi: 10.3389/fonc.2013.00049. eCollection 2013. Front Oncol. 2013. PMID: 23508517 Free PMC article.
Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT, Murthy S, Finke J, Sergi J, Gibson V, Medendorp S, Barna B, Boyett J, Bukowski RM. Budd GT, et al. Among authors: finke j. J Clin Oncol. 1992 May;10(5):804-9. doi: 10.1200/JCO.1992.10.5.804. J Clin Oncol. 1992. PMID: 1569452 Clinical Trial.
Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
Gautam SC, Chikkala NF, Lewis I, Grabowski DR, Finke JH, Ganapathi R. Gautam SC, et al. Among authors: finke jh. Anticancer Res. 1992 May-Jun;12(3):921-5. Anticancer Res. 1992. PMID: 1622150
In vitro activation of lymphocytes by interleukin 2 in patients with renal cell carcinoma.
Ziegelbaum MM, Finke JH, Tubbs R, Montie JE, Pontes JE, Lewis I. Ziegelbaum MM, et al. Among authors: finke jh. Urology. 1989 Feb;33(2):106-9. doi: 10.1016/0090-4295(89)90005-8. Urology. 1989. PMID: 2783793
Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes.
Wang Q, Redovan C, Tubbs R, Olencki T, Klein E, Kudoh S, Finke J, Bukowski RM. Wang Q, et al. Among authors: finke j. Int J Cancer. 1995 Jun 9;61(6):780-5. doi: 10.1002/ijc.2910610607. Int J Cancer. 1995. PMID: 7790111
Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.
Finke JH, Rayman P, Hart L, Alexander JP, Edinger MG, Tubbs RR, Klein E, Tuason L, Bukowski RM. Finke JH, et al. J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):91-104. doi: 10.1097/00002371-199402000-00002. J Immunother Emphasis Tumor Immunol. 1994. PMID: 7907918
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, O'Shea JJ, Kudoh S, Klein E, et al. Finke JH, et al. Cancer Res. 1993 Dec 1;53(23):5613-6. Cancer Res. 1993. PMID: 8242613
Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects.
Bukowski RM, Budd GT, Gibbons JA, Bauer RJ, Childs A, Antal J, Finke J, Tuason L, Lorenzi V, McLain D, et al. Bukowski RM, et al. Among authors: finke j. J Clin Oncol. 1994 Jan;12(1):97-106. doi: 10.1200/JCO.1994.12.1.97. J Clin Oncol. 1994. PMID: 8270990 Clinical Trial.
Interleukin 7 enhances the proliferation and effector function of tumor-infiltrating lymphocytes from renal-cell carcinoma.
Sica D, Rayman P, Stanley J, Edinger M, Tubbs RR, Klein E, Bukowski R, Finke JH. Sica D, et al. Among authors: finke jh. Int J Cancer. 1993 Apr 1;53(6):941-7. doi: 10.1002/ijc.2910530613. Int J Cancer. 1993. PMID: 8473051
Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas.
Kolenko V, Wang Q, Riedy MC, O'Shea J, Ritz J, Cathcart MK, Rayman P, Tubbs R, Edinger M, Novick A, Bukowski R, Finke J. Kolenko V, et al. Among authors: finke j. J Immunol. 1997 Sep 15;159(6):3057-67. J Immunol. 1997. PMID: 9300731
128 results
Jump to page